Key Takeaways Microbot gained a U.S. patent expanding LIBERTY's applications with modular tool-receiver units.The new patent increases Microbot's U.S. market opportunity from 2.5M to over 6M procedures.Shares have risen 7.1% after the news, with year-to-date gains of 195.5% against industry decline.Microbot Medical Inc. (MBOT) has been granted a new U.S. patent that broadens the potential applications of its LIBERTY Endovascular Robotic System. The patent covers a modular design that allows interchangeable ...

With the Newly Granted IP, the Company’s IP Portfolio for the LIBERTY® System now includes 12 patents granted globally and 57 patent applications pending. The Company Continues to Scale Commercial Readiness Plans for the LIBERTY® System as it Awaits FDA Decision. HINGHAM, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced that the United States Patent and Trademark Office (USPTO) has granted the Com ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____ to _____ Commission file number: 000-19871 175 Derby St., Bld. 27 Hingham, MA 02043 (Address of principal executive of ices) (781) 875-3605 (Registrant's T ...

Core Insights - Microbot Medical Inc. is participating in the inaugural Endovascular Robotics session at the Society of Robotic Surgery (SRS) annual meeting, highlighting the growth and innovation in the endovascular robotics field driven by market demand [1][3] - The session will feature discussions on emerging technologies in the peripheral vascular, neurovascular, and cardiovascular spaces, with a focus on educating the medical community about the LIBERTY Endovascular Robotic System [2][3] - The SRS aims to foster education and collaboration in robotic surgery, providing opportunities for multi-centric studies and training for young professionals in the field [4] Company Overview - Microbot Medical is a pre-commercial stage medical technology company focused on redefining endovascular robotics and improving patient care globally [6] - The company has developed the world's first single-use, fully disposable endovascular robotic system, which aims to remove barriers to accessing advanced robotic systems [6] - The LIBERTY system is currently pending FDA 510(k) clearance and is not available for sale in the U.S. as the company strengthens its sales and marketing infrastructure for its launch [5]

Core Insights - Microbot Medical Inc. has been added to the Russell Microcap Index, effective June 30, 2025, enhancing its visibility in the market [1][2] - The inclusion reflects the company's strong execution and momentum, particularly in relation to its LIBERTY Endovascular Robotic System and ongoing FDA interactions [2] - The Russell US Indexes reconstitution captures the 4,000 largest US stocks, and membership in the Russell Microcap Index ensures automatic inclusion in relevant growth and value style indexes [2][3] Company Overview - Microbot Medical is a pre-commercial stage medical technology company focused on redefining endovascular robotics to improve patient care globally [4] - The company has developed the world's first single-use, fully disposable endovascular robotic system, aiming to overcome traditional barriers to advanced robotic systems [4] Market Context - Russell indexes are widely utilized by investment managers and institutional investors, serving as benchmarks for approximately $10.6 trillion in assets as of June 2024 [3]

Core Insights - Microbot Medical Inc. has been granted a critical patent in China for its LIBERTY Endovascular Robotic System, marking a significant step in its global intellectual property expansion strategy [1] - The company currently holds nine patents globally and has 59 pending patent applications, which helps maintain a competitive advantage and protect the unique capabilities of the LIBERTY System [2] - Preparations for the anticipated U.S. launch of the LIBERTY System are underway, with regulatory, operational, and commercial activities accelerating [3] - The company aims to impact both developed and emerging markets, with an estimated 2 million peripheral endovascular procedures performed annually in the U.S. and approximately 2.9 million in China [4] - Microbot Medical is focused on redefining endovascular robotics and improving patient care through its innovative, single-use, fully disposable robotic system [5]

Core Viewpoint - Microbot Medical Inc. (MBOT) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is primarily driven by changes in a company's earnings picture, with the Zacks Consensus Estimate reflecting EPS estimates from sell-side analysts [2]. - The Zacks rating upgrade for Microbot Medical signifies an optimistic earnings outlook, likely leading to increased buying pressure and a rise in stock price [4][6]. Impact of Earnings Estimate Revisions - Changes in future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements, particularly due to institutional investors' reliance on these estimates for fair value calculations [5]. - For Microbot Medical, the recent increase in earnings estimates suggests an improvement in the company's underlying business, which should positively influence stock performance [6]. Performance of Zacks Rank System - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [8]. - The upgrade of Microbot Medical to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [11]. Recent Earnings Estimate Trends - For the fiscal year ending December 2025, Microbot Medical is expected to earn -$0.32 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 38.5% over the past three months [9].

Core Insights - Microbot Medical Inc. is expanding its commercial team in anticipation of the U.S. launch of the LIBERTY Endovascular Robotic System, projected for the third quarter of 2025 [1][2] - The company is actively engaged with the FDA, expecting a 510(k) decision during the third quarter of this year, which aligns with the FDA's original review timeline [1][4] - The addition of Michael Lytle as the head of Sales Operations & Analytics is aimed at enhancing sales infrastructure and optimizing the sales cycle [2][3] Company Developments - The LIBERTY System is currently under FDA review and is not available for sale in the U.S. until clearance is granted [4] - Michael Lytle's previous experience at ZOLL Cardiac Management Solutions is expected to contribute to the company's market targeting and resource allocation [3] - The company aims to redefine endovascular robotics and improve patient care through its innovative, single-use, fully disposable robotic system [5]

Group 1 - Microbot Medical Inc. has been selected for inclusion in the preliminary list of additions to the Russell Microcap Index, effective after U.S. market close on June 27, 2025 [1] - Membership in the Russell Microcap Index is determined by market capitalization rankings and style attributes, and it remains in place for one year [2] - Russell indexes are utilized by investment managers and institutional investors for index funds and serve as benchmarks for approximately $10.6 trillion in assets as of June 2024 [3] Group 2 - Microbot Medical is a pre-commercial stage medical technology company focused on improving patient care globally [4] - The company has developed the LIBERTY Endovascular Robotic System, which is the world's first single-use, fully disposable endovascular robotic system [4]

Part I [Financial Statements](index=4&type=section&id=Item%201%20-%20Financial%20Statements) Microbot Medical Inc.'s unaudited interim financial statements as of March 31, 2025, show total assets increased to $30.9 million, a net loss of $2.6 million, and strong financing cash inflows of $27.8 million [Interim Condensed Consolidated Balance Sheets](index=4&type=section&id=Interim%20Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2025, total assets significantly increased to $30.9 million, driven by marketable securities, while shareholders' equity grew to $29.0 million due to capital raises Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2025 (Unaudited) | December 31, 2024 (Audited) | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $3,217 | $3,114 | | Marketable securities | $27,173 | $2,356 | | Total current assets | $30,656 | $5,819 | | **Total assets** | **$30,892** | **$6,031** | | **Liabilities & Equity** | | | | Total current liabilities | $1,893 | $2,460 | | Total liabilities | $1,941 | $2,501 | | Total shareholders' equity | $28,951 | $3,530 | | **Total liabilities and shareholders' equity** | **$30,892** | **$6,031** | [Interim Condensed Consolidated Statements of Comprehensive Loss](index=5&type=section&id=Interim%20Condensed%20Consolidated%20Statements%20of%20Comprehensive%20Loss) For Q1 2025, the company reported a net loss of $2.6 million, an increase from $2.4 million in Q1 2024, primarily due to higher R&D and G&A expenses Statements of Comprehensive Loss (in thousands, except per share data) | Metric | Q1 2025 (Unaudited) | Q1 2024 (Unaudited) | | :--- | :--- | :--- | | Research and development, net | $(1,459) | $(1,169) | | General and administrative | $(1,562) | $(1,215) | | Operating loss | $(3,021) | $(2,384) | | Other income | $316 | $0 | | Net loss | $(2,601) | $(2,371) | | Basic and diluted net loss per share | $(0.08) | $(0.17) | | Weighted average common shares outstanding | 31,085,606 | 14,055,973 | [Interim Condensed Consolidated Statements of Shareholders' Equity](index=6&type=section&id=Interim%20Condensed%20Consolidated%20Statements%20of%20Shareholders'%20Equity) Shareholders' equity significantly increased to $29.0 million by March 31, 2025, primarily driven by $25.9 million from common stock and warrant issuances and $1.0 million from ATM offerings - In Q1 2025, the company issued 13,891,840 shares of common stock and warrants, raising **$25.9 million** net of issuance costs[15](index=15&type=chunk) - An additional 842,606 shares were issued under the at-the-market (ATM) offering program, generating **$997,000** net of costs[15](index=15&type=chunk) - The exercise of 610,517 warrants brought in an additional **$852,000**[15](index=15&type=chunk) [Interim Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Interim%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) In Q1 2025, net cash used in operating activities was $2.9 million and investing activities $24.8 million, offset by $27.8 million from financing activities, resulting in a $102,000 increase in cash Statements of Cash Flows Highlights (in thousands) | Activity | Q1 2025 (Unaudited) | Q1 2024 (Unaudited) | | :--- | :--- | :--- | | Net cash flows used in operating activities | $(2,874) | $(2,420) | | Net cash flows used in investing activities | $(24,830) | $(1,284) | | Net cash flows provided by financing activities | $27,806 | $2,397 | | **Increase (decrease) in cash, cash equivalents and restricted cash** | **$102** | **$(1,307)** | [Notes to Interim Unaudited Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Interim%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) The notes detail the company's pre-commercial status, sufficient funding for over twelve months, ongoing monitoring of geopolitical risks, grant obligations, and significant share capital activities - The company is a pre-commercial, clinical-stage medical device company focused on robotic endoluminal surgery devices[22](index=22&type=chunk) - Management has concluded that available funds are sufficient to fund operations for **more than twelve months** from the financial statement issuance date[26](index=26&type=chunk) - The company has received grants from the Israeli Innovation Authority (IIA) and is obligated to pay royalties of **3.0%-5%** on future sales of related products[48](index=48&type=chunk)[49](index=49&type=chunk) - In Q1 2025, the company raised approximately **$28.6 million** in gross proceeds through registered direct offerings and private placements[67](index=67&type=chunk)[68](index=68&type=chunk)[69](index=69&type=chunk) - Subsequent to the quarter end, in April and May 2025, the company raised an additional **$2.56 million** from the exercise of preferred investment options[85](index=85&type=chunk)[86](index=86&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=19&type=section&id=Item%202%20-%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's pre-commercial status, the LIBERTY system's FDA 510(k) submission, strengthened financial condition from **$31.8 million** in capital raises, and increased R&D and G&A expenses in Q1 2025 - The company is a pre-commercial, clinical-stage medical device company developing the **LIBERTY Endovascular Robotic Surgical System**, the first fully disposable robot for endovascular procedures[90](index=90&type=chunk)[91](index=91&type=chunk) - A **510(k) premarket notification** for the LIBERTY system was submitted to the FDA on December 10, 2024, with marketing clearance anticipated in **Q2 2025**[100](index=100&type=chunk)[101](index=101&type=chunk) - The company raised approximately **$31.8 million** in gross proceeds since January 1, 2025, through various offerings and warrant exercises[126](index=126&type=chunk) - Management believes the company has sufficient funds for its operations for **in excess of one year** as of the filing date[128](index=128&type=chunk) [Results of Operations](index=23&type=section&id=MD%26A%20-%20Results%20of%20Operations) In Q1 2025, R&D expenses increased by **$290,000** and G&A expenses by **$347,000**, while other income of **$316,000** was recognized from a litigation settlement Comparison of Results of Operations (in thousands) | Expense/Income | Q1 2025 | Q1 2024 | Change | | :--- | :--- | :--- | :--- | | Research and development expenses, net | $(1,459) | $(1,169) | $(290) | | General and administrative expenses | $(1,562) | $(1,215) | $(347) | | Other income | $316 | $0 | $316 | | Financing income, net | $104 | $13 | $91 | - The increase in R&D expenses was primarily due to an increase in payroll and manufacturing of the **LIBERTY product**[118](index=118&type=chunk) - The increase in G&A expenses was primarily due to increases in payroll, professional services, rent, and travel expenses[119](index=119&type=chunk) [Liquidity and Capital Resources](index=24&type=section&id=MD%26A%20-%20Liquidity%20and%20Capital%20Resources) The company's net working capital significantly increased to **$28.8 million** by March 31, 2025, supported by approximately **$31.8 million** in gross proceeds from financing activities since January 1, 2025 - As of March 31, 2025, the company had net working capital of approximately **$28.8 million**[121](index=121&type=chunk) - Since January 1, 2025, the company has raised significant capital, including approximately **$15.6 million** and **$13.0 million** from institutional investors in January and February, respectively, and additional funds from ATM sales and warrant exercises[126](index=126&type=chunk) Summary of Net Cash Flow (in thousands) | Activity | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net cash flows used in operating activities | $(2,874) | $(2,420) | | Net cash flows used in investing activities | $(24,830) | $(1,284) | | Net cash flows provided by financing activities | $27,806 | $2,397 | [Quantitative and Qualitative Disclosures About Market Risk](index=25&type=section&id=Item%203%20-%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risk is interest rate sensitivity on short-term instruments, with foreign exchange risk from non-USD operating expenses, while inflation has not significantly impacted operations - Primary market risk is interest income sensitivity on cash and marketable securities, but the **short-term nature** of these instruments mitigates this risk[131](index=131&type=chunk) - The company has foreign exchange risk as a significant portion of its operating expenses are in currencies other than the U.S. dollar[132](index=132&type=chunk) - Inflation is not considered to have had a significant impact on the company's results of operations[134](index=134&type=chunk) [Controls and Procedures](index=26&type=section&id=Item%204%20-%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of March 31, 2025, with no material changes in internal control over financial reporting during the quarter - Management concluded that as of March 31, 2025, the company's disclosure controls and procedures were **effective**[135](index=135&type=chunk) - No changes in internal control over financial reporting occurred during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, internal controls[136](index=136&type=chunk) Part II [Legal Proceedings](index=26&type=section&id=Item%201%20-%20Legal%20Proceedings) Information on legal proceedings is disclosed in Note 3G, detailing the favorable outcome of the Mona litigation, which resulted in the company receiving approximately **$316,000** - For information on legal proceedings, the report refers to **Note 3G** of the financial statements[138](index=138&type=chunk) - Note 3G describes the Mona litigation, where an appellate court ruled in the company's favor, resulting in a judgment of approximately **$316,000**, which was recorded as other income[65](index=65&type=chunk) [Risk Factors](index=26&type=section&id=Item%201A%20-%20Risk%20Factors) This section is not required for a smaller reporting company, and therefore no information is provided - Disclosure of risk factors is not required as the company is classified as a **smaller reporting company**[139](index=139&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=26&type=section&id=Item%202%20-%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported several unregistered sales of common stock from preferred investment option exercises, raising approximately **$916,000** in January 2025, **$2.3 million** in April 2025, and **$262,500** in May 2025 - In January 2025, the company issued 610,517 shares of common stock upon the exercise of Series E options, generating gross proceeds of approximately **$916,000**[140](index=140&type=chunk) - In April 2025, the company issued 1,533,336 shares upon exercise of Series E and F options, generating gross proceeds of approximately **$2,300,000**[141](index=141&type=chunk) - In May 2025, the company issued 175,000 shares upon exercise of Series F options, generating gross proceeds of approximately **$262,500**[142](index=142&type=chunk) [Other Information](index=28&type=section&id=Item%205%20-%20Other%20Information) During the first quarter of 2025, no director or officer of the company adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement - No director or officer adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement during the three months ended March 31, 2025[145](index=145&type=chunk) [Exhibits](index=28&type=section&id=Item%206%20-%20Exhibits) This section lists all exhibits filed with the Form 10-Q, including merger agreements, corporate governance documents, forms of warrants and investment options, securities purchase agreements, and officer certifications